Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 4, 2011, Pages 401-406

  Anderson, Phillip R ^a   Gogo, Prospero B ^a   Ahmed, Bina ^a   Straight, Faye ^a   Terrien, Edward F ^a   Watkins, Matthew W ^a   Gharib, Nader El ^a   Dauerman, Harold L ^a  

^a FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Bivalrudin; STEMI; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE STENT THROMBOSIS; ADULT; ARTICLE; BLEEDING; CONTINUOUS INFUSION; DRUG ELUTING STENT; DRUG INFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; AGED; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; HEART INFARCTION; MIDDLE AGED; STENT; THROMBOSIS; TIME;

AGED; ANTITHROMBINS; CORONARY ARTERY BYPASS; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; REGISTRIES; STENTS; THROMBOSIS; TIME FACTORS;

EID: 80052337285     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-010-0528-7     Document Type: Article

References (19)

1. Dauerman HL, Frederick PD, Miller D, French WJ (2007) Current incidence and clinical outcomes of bivalirudin administration among patients undergoing primary coronary intervention for stent thrombosis elevation acute myocardial infarction. Coron Artery Dis 18(2):141-148
2. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (horizons-ami): 1-year results of a randomised controlled trial. Lancet 374(9696):1149-1159
3. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R (2008) Bivalirudin during primary pci in acute myocardial infarction. N Engl J Med 358(21):2218-2230 (Pubitemid 351724451)
4. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111(20):2560-2564 (Pubitemid 40740853)
5. Ahmed B, Lischke S, Straight F, Gogo P, Leffler S, Kutler M, Schneider DJ, Dauerman HL (2009) Consistent door-to-balloon times of less than 90 min for stemi patients transferred for primary pci. J Invasive Cardiol 21(9):429-433
6. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW (2008) The harmonizing outcomes with revascularization and stents in acute myocardial infarction (horizons-ami) trial: study design and rationale. Am Heart J 156(1):44-56 (Pubitemid 351862292)
7. Ahmed B, Piper WD, Malenka D, VerLee P, Robb J, Ryan T, Herne M, Phillips W, Dauerman HL (2009) Significantly improved vascular complications among women undergoing percutaneous coronary intervention: a report from the northern new england percutaneous coronary intervention registry. Circ Cardiovasc Interv 2(5):423-429
8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17):2344-2351 (Pubitemid 46685903)
9. Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, Shaw RE, Roe MT, Ho KK, Klein LW, Krone RJ, Weintraub WS, Brindis RG, Rumsfeld JS, Spertus JA (2010) Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588, 398 procedures in the national cardiovascular data registry. J Am Coll Cardiol 55(18):1923-1932
10. Elbarouni B, Goodman SG, Yan RT, Welsh RC, Kornder JM, Deyoung JP, Wong GC, Rose B, Grondin FR, Gallo R, Tan M, Casanova A, Eagle KA, Yan AT (2009) Validation of the global registry of acute coronary event (grace) risk score for in-hospital mortality in patients with acute coronary syndrome in canada. Am Heart J 158(3):392-399
11. Dauerman HL, Lessard D, Yarzebski J, Gore JM, Goldberg RJ (2005) Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol 96(10):1379-1383 (Pubitemid 41566617)
12. Kereiakes DJ, Choo JK, Young JJ, Broderick TM (2004) Thrombosis and drug-eluting stents: a critical appraisal. Rev Cardiovasc Med 5(1):9-15 (Pubitemid 38344495)
13. Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Rabbani LE, Parise H, Stone GW (2009) Role of clopidogrel loading dose in patients with st-segment elevation myocardial infarction undergoing primary angioplasty: results from the horizons-ami (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 54(15):1438-1446
14. Antman EM, Wiviott SD, Murphy SA, Voitk J, Hasin Y, Widimsky P, Chandna H, Macias W, McCabe CH, Braunwald E (2008) Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a tritontimi 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction) analysis. J Am Coll Cardiol 51(21): 2028-2033 (Pubitemid 351689056)
15. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ (2007) Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the acuity trial. JAMA 298(21):2497-2506 (Pubitemid 350223536)
16. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV (2007) Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the replace-2 trial. Am J Cardiol 100(9): 1364-1369 (Pubitemid 47576015)
17. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B (1995) Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog angioplasty study investigators. N Engl J Med 333(12): 764-769
18. Piper WD, Malenka DJ, Ryan TJ Jr, Shubrooks SJ Jr, O'Connor GT, Robb JF, Farrell KL, Corliss MS, Hearne MJ, Kellett MA Jr, Watkins MW, Bradley WA, Hettleman BD, Silver TM, McGrath PD, O'Mears JR, Wennberg DE (2003) Predicting vascular complications in percutaneous coronary interventions. Am Heart J 145(6):1022-1029 (Pubitemid 36688253)
19. Sanborn TA, Ebrahimi R, Manoukian SV, McLaurin BT, Cox DA, Feit F, Hamon M, Mehran R, Stone GW (2010) Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: the acute catheterization and urgent intervention triage strategy (acuity) trial. Circ Cardiovasc Interv 3(1):57-62